KLOW Research Overview (also known as GHK-Cu + TB-500 + BPC-157 + KPV)
KLOW is a research peptide combination that builds upon the GLOW protocol by adding KPV for enhanced anti-inflammatory effects. This 80mg blend typically contains 50mg GHK-Cu, 10mg TB-500, 10mg BPC-157, and 10mg KPV in a 5:1:1:1 ratio. While individual components have varying levels of research support, no clinical trials have examined this specific four-peptide combination. The protocol remains investigational with theoretical benefits based on complementary mechanisms.
What Is KLOW Protocol?
KLOW is a research peptide combination that builds upon the GLOW protocol by adding KPV for enhanced anti-inflammatory effects. This 80mg blend typically contains 50mg GHK-Cu, 10mg TB-500, 10mg BPC-157, and 10mg KPV in a 5:1:1:1 ratio. While individual components have varying levels of research support, no clinical trials have examined this specific four-peptide combination. The protocol remains investigational with theoretical benefits based on complementary mechanisms.
Mechanism of Action
Each peptide contributes different mechanisms: GHK-Cu modulates genes, TB-500 enhances cell migration, BPC-157 upregulates growth factors, KPV inhibits NF-κB
Key Benefits
Theoretical synergistic effects from four peptides - tissue repair, anti-inflammation, cellular regeneration
Quick Reference
| Literature-Reported Dose Range | 2-3.2mg daily (0.1-0.16mL at 20mg/mL) |
| Literature-Reported Frequency | Once daily, typically evening |
| Literature-Reported Cycle Length | 4-6 weeks typical |
| Literature-Reported Washout | 2-4 weeks reported |
| Storage | Must refrigerate after reconstitution |
| Sites Reported in Studies | Subcutaneous: Rotate between abdomen, thighs, upper arms |
| Timing | Evening administration common but not studied |
Research Indications
Wound Healing
Multi-Modal Healing
Addresses tissue repair through multiple complementary pathways
Enhanced Tolerability
KPV may reduce injection site reactions compared to GLOW
Convenience Factor
Single injection versus four separate peptides
Recovery
Post-Surgical Recovery
User reports of enhanced healing - no clinical validation
Sports Injury Support
Athletes report benefits - banned by WADA
Skin Rejuvenation
Aesthetic applications reported but unverified
Anti-Inflammatory
No Safety Data
Long-term effects of combination unknown
Quality Control Issues
Unregulated market with contamination risks
Dosing Uncertainty
No optimization studies for ratios or total dose
Research Protocols
Unit Mapping Reference
KLOW is a 50/10/10/10 mg blend (GHK-Cu / BPC-157 / TB-500 / KPV). Reconstituted in 3 mL (300 units): 6 units = 1.0 mg GHK-Cu + 0.2 mg each BPC-157, TB-500, KPV | 9 units = 1.5 mg GHK-Cu + 0.3 mg each | 12 units = 2.0 mg GHK-Cu + 0.4 mg each | 15 units = 2.5 mg GHK-Cu + 0.5 mg each. Researchers pick a daily pull and hold it steady across the cycle.
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
| Research Application | Dose | Frequency | Route |
|---|
| Skin / Aesthetic / Scar | 1–2 mg/day (6–12 units) | Once daily | SubQ |
| Wound Healing / Injury Recovery | 2–2.5 mg/day (12–15 units) | Once daily | SubQ |
Timing
Administer once daily, SubQ. Research patterns fall in the 2.0–3.2 mg total blend per day range. Start at a target tier and hold steady — pushing higher mainly increases exposure and cost; it does not guarantee better outcomes, and long-term safety for the four-peptide combination is unknown. After an initial 4–8 week observation window, step down to the maintenance tier to see whether improvements in skin, joint comfort, or gut symptoms persist with lower exposure.
Peptide Interactions
KLOW already contains all GLOW components plus KPV - combining would result in double dosing of base peptides
No studies on combination - theoretical compatibility based on different mechanisms
No data on combining KLOW with NAD+ - both affect cellular processes through different pathways
Components may affect wound healing and clotting - medical supervision required
Multiple components affect GH pathways - risk of excessive stimulation
Components may interfere with immunosuppressive therapy - consult physician
Reported Research Timeline
01Early (1–2 weeks) (reported in cited studies): subtle shifts in skin hydration and "glow." Reduced local irritation, soreness, or swelling around injured areas consistent with BPC-157/TB-500 effects. Some individuals with high baseline inflammation report early changes in gut comfort or eczema/psoriasis-type symptoms — not consistent or guaranteed.
02Intermediate (2–4+ weeks): More visible improvements in skin texture, firmness, elasticity, and scar appearance as GHK-Cu drives collagen and ECM signaling. Tendon, ligament, and muscle repair models show better structural healing aligned with BPC-157/TB-500 work. KPV immune-modulating effects may appear as reduced flare frequency or intensity in tracked gut or skin conditions.
03Systemic / longer-range: Framed as a broad repair and inflammation-modulating stack — exploratory designs track shifts in training tolerance, joint comfort, recovery from hard training blocks, and skin/gut baseline over repeated cycles.
04Human timelines and dose-response curves for this fixed four-peptide ratio are not formally mapped. KLOW sits squarely in the exploratory research category — careful dose math, structured cycles, and observation matter more than pushing high unit counts.
Safety Notes
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
No safety studies on four-peptide combination
Individual peptides generally well-tolerated in research
Injection site reactions common even with KPV
Long-term effects completely unknown
FDA has not approved any component for therapeutic use
Quality and contamination risks in unregulated market
Seek Medical Attention If:
Severe injection site reactions or infection
Allergic reactions (rash, difficulty breathing)
Unusual fatigue or weakness
Signs of copper toxicity (nausea, jaundice)
Any concerning symptoms - no safety net exists
Worsening of underlying conditions
Quality Indicators
Verified Marker
Third-party testing
Look for Janoshik or similar analytical verification
Verified Marker
Reputable research supplier
Established vendors with quality control processes
Acceptable Range
Research-only status
Not approved for human use - research purposes only
Acceptable Range
Batch variability
Ratios and purity may vary between batches
Quality Concern
No COA provided
Avoid vendors without certificates of analysis
Quality Concern
Suspiciously low pricing
Quality peptides are expensive - very low prices suggest counterfeits
Research Citations
- Individual Component Research - GHK-Cu (Multiple Studies)
Human studies | Various protocols | 40+ years research - BPC-157 Limited Human Data (2020)
Human pilot | 12 patients | Interstitial cystitis - No Published Studies on KLOW Combination
No clinical trials | No safety studies | No peer-reviewed research - Two-Peptide Combinations Only (Various)
Limited research | BPC-157 + TB-500 | Animal models
Research Focus
woundHealing, recovery, antiInflammatory
Verified Vendors Carrying KLOW
Frequently Asked Questions
What should researchers watch for with KLOW?
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
What should researchers expect over time with KLOW?
Early (1–2 weeks) (reported in cited studies): subtle shifts in skin hydration and "glow." Reduced local irritation, soreness, or swelling around injured areas consistent with BPC-157/TB-500 effects. Some individuals with high baseline inflammation report early changes in gut comfort or eczema/psoriasis-type symptoms — not consistent or guaranteed.
How is KLOW typically administered in research?
Unit Mapping Reference
Browse all peptides in the Encyclopedia →